The global Lymphoma Treatment Market was valued at $7.01 billion in 2023, projected to reach $14.66 billion by 2032, with a CAGR of 8.54%. Factors driving growth include increasing prevalence of Hodgkin and non-Hodgkin lymphoma, immunotherapy trends, and research and development activities. Technological advances and rising obesity also contribute to market expansion.

The U.S. lymphoma treatment market was estimated at $2.71 billion in 2023 and is expected to reach $5.50 billion by 2032, with a CAGR of 8.20%. North America, particularly the U.S., dominates the market due to a robust healthcare infrastructure and the adoption of next-generation drugs like CAR-T cell therapies. Major players in the market include AstraZeneca, Bayer AG, Takeda Pharmaceutical, and more.

Non-Hodgkin Lymphoma is the largest segment in the market, accounting for 85.54% in 2023. This segment requires complex and long-term therapeutic strategies, including chemotherapy, immunotherapy, and advanced targeted therapies. Rituxan/MabThera is the leading segment in lymphoma treatment by drug, with a 22% market share due to its effectiveness in combination with chemotherapy.

Hospitals dominate the distribution channel segment of the lymphoma treatment market, accounting for 37% in 2023. Hospitals provide advanced, specialized care for complex oncology therapies like immunotherapies, chemotherapy, and CAR-T cell therapies. North America leads the market with a 52% share, while Asia-Pacific is projected to register the highest CAGR due to rising healthcare infrastructure and better access to cancer care.

The APAC region is expected to register the highest CAGR in the lymphoma treatment market due to increasing healthcare infrastructure, prevalence of lymphoma, and better access to cancer care. Governments in countries like China and India are investing in healthcare infrastructure upgrades and local biotech innovation to drive treatment adoption.

Read more at GlobeNewswire: Lymphoma Treatment Market to Surpass USD 14.66 Billion by